Sanofi and Sebia Develop New Monoclonal Protein Detection Test in Multiple Myeloma
Sanofi and Sebia Develop New Monoclonal Protein Detection Test in Multiple Myeloma image
Sanofi and Sebia Develop New Monoclonal Protein Detection Test in Multiple Myeloma
Posted Jan 27, 2020

In myeloma, it is known that patients who are taking monoclonal antibodies that target CD38 can have "detectable" levels of a monoclonal protein, when those levels are actually related to the monoclonal antibody itself. This can confuse patients and their doctors who could believe that they still have detectable myeloma when they in fact do not.

Sanofi is hopeful of FDA approval of their new CD38 monoclonal antibody isatuximab some time this year and is proactively partnering with Sebia to develop a myeloma test that will take this into account when measuring monoclonal protein. 

The typical Immunoelectrophoresis test (IFE) is used to measure monoclonal protein in the blood and is a key marker patients and doctors watch to determine the activity of the myeloma and response to treatment.  Sebia is a diagnostics company that is making a proprietary IFE test called Hydragel. The partnership is covering the development of an Hydrashift 2/4 isatuximab in vitro diagnostic kit which will prevent isatuximab from inaccurately affecting Sebia’s IFE test results.

Sebia has also partnered with Janssen to offer a similar but customized test for daratumumab patients (also a CD38 monoclonal antibody). 

Sanofi and Sebia will apply for a European Union CE Mark and will also request approval from the FDA. Jean-Marc Chermette, CEO of Sebia said: 

“We are excited about partnering with Sanofi and further developing our Immunofixation range of products. The future Hydrashift 2/4 isatuximab test is in line with our strategy of developing innovative and advanced products for patient care,” said Jean-Marc Chermette, CEO at Sebia. “This development confirms Sebia’s commitment and strategic objective to remain the market leader in providing the most advanced diagnostic tools supporting multiple myeloma disease management.”

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811